Haidan Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Haidan Chen has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Can Zhuo
Department of Spinal Surgery, The First College of Clinical Medical Science, China Three Gorges University & Yichang Central People’s Hospital, Yichang, Hubei, 443000, People’s Republic of China
7 shared publicationsSiyu Jia
5 shared publicationsYang Liu
Yichang Central People’s Hospital, The First Clinical Medical College of China Three Gorges University, Yichang, China
5 shared publicationsBoya Gong
4 shared publicationsShiwen Chen
Department of the Spinal Surgery, The First College of Clinical Medical Science (Yichang Central People’s Hospital),China Three Gorges University, Yichang, China
4 shared publicationsDiao Yang
Department of the Spinal Surgery, The First College of Clinical Medical Science (Yichang Central People’s Hospital),China Three Gorges University, Yichang, China
3 shared publications
Latest Publications
- Open Access
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1873276
Case Report: Intravascular large B-cell lymphoma presenting with cauda equina syndrome: a rare case and diagnostic dilemma
Objective: To investigate the clinical and diagnostic characteristics of intravascular large B-cell lymphoma (IVLBCL) presenting primarily as cauda equina syndrome (CES), analyze factors contributing to diagnostic delay, and evaluate the diagnostic value of minimally invasive biopsy. Methods: We report a case of IVLBCL that initially presented with CES. The diagnostic process was reviewed by analyzing serum biomarkers and pathology from a random skin biopsy (RSB) that included subcutaneous fat tissue. Additionally, a literature review was conducted via the PubMed database (2005–2025), which identified and analyzed 10 additional cases of IVLBCL with CES as the initial manifestation. Imaging features, clinical symptoms, and time-to-diagnosis were synthesized across these cases. Results: In the present case, the patient presented with progressive lower extremity weakness, saddle anesthesia, and sphincter dysfunction, while early spinal MRI findings were unrevealing. Diagnostically, markedly elevated lactate dehydrogenase (LDH) and interleukin-10 (IL-10) provided key clues, and definitive diagnosis was achieved via a multi-site incisional RSB including subcutaneous fat. In comparison, the 10 literature-retrieved cases ( n = 11 in total) universally demonstrated typical CES but posed significant diagnostic challenges due to the non-specificity of early symptoms and high heterogeneity on initial spinal MRI, which frequently lacked direct space-occupying evidence or appeared entirely normal. Conclusion: Clinicians should maintain a high index of suspicion for IVLBCL in patients presenting with CES when initial imaging findings fail to reflect the clinical severity, particularly when accompanied by systemic laboratory abnormalities such as elevated LDH. While serum IL-10 may serve as a potentially useful adjunctive biomarker to raise diagnostic suspicion, prompt initiation of a RSB enables early detection of this disease and minimizes diagnostic delays.
- 5 August 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1873276
Open AccessCase Report: Intravascular large B-cell lymphoma presenting with cauda equina syndrome: a rare case and diagnostic dilemma
Objective: To investigate the clinical and diagnostic characteristics of intravascular large B-cell lymphoma (IVLBCL) presenting primarily as cauda equina syndrome (CES), analyze factors contributing to diagnostic delay, and evaluate the diagnostic value of minimally invasive biopsy. Methods: We report a case of IVLBCL that initially presented with CES. The diagnostic process was reviewed by analyzing serum biomarkers and pathology from a random skin biopsy (RSB) that included subcutaneous fat tissue. Additionally, a literature review was conducted via the PubMed database (2005–2025), which identified and analyzed 10 additional cases of IVLBCL with CES as the initial manifestation. Imaging features, clinical symptoms, and time-to-diagnosis were synthesized across these cases. Results: In the present case, the patient presented with progressive lower extremity weakness, saddle anesthesia, and sphincter dysfunction, while early spinal MRI findings were unrevealing. Diagnostically, markedly elevated lactate dehydrogenase (LDH) and interleukin-10 (IL-10) provided key clues, and definitive diagnosis was achieved via a multi-site incisional RSB including subcutaneous fat. In comparison, the 10 literature-retrieved cases ( n = 11 in total) universally demonstrated typical CES but posed significant diagnostic challenges due to the non-specificity of early symptoms and high heterogeneity on initial spinal MRI, which frequently lacked direct space-occupying evidence or appeared entirely normal. Conclusion: Clinicians should maintain a high index of suspicion for IVLBCL in patients presenting with CES when initial imaging findings fail to reflect the clinical severity, particularly when accompanied by systemic laboratory abnormalities such as elevated LDH. While serum IL-10 may serve as a potentially useful adjunctive biomarker to raise diagnostic suspicion, prompt initiation of a RSB enables early detection of this disease and minimizes diagnostic delays.
- Open Access
- 12 July 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Chromogenic factor X-guided warfarin monitoring in lupus anticoagulant-positive primary antiphospholipid syndrome with adrenal hemorrhage and progressive deep vein thrombosis: a case report
Antiphospholipid syndrome (APS) is a thrombotic autoimmune disorder; adrenal hemorrhage is uncommon. Treating progressive thrombosis with concurrent major
- 12 July 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessChromogenic factor X-guided warfarin monitoring in lupus anticoagulant-positive primary antiphospholipid syndrome with adrenal hemorrhage and progressive deep vein thrombosis: a case report
Antiphospholipid syndrome (APS) is a thrombotic autoimmune disorder; adrenal hemorrhage is uncommon. Treating progressive thrombosis with concurrent major
- Open Access
- 1 May 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-21
Nanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational Challenges
Melittin, a 26-amino-acid amphipathic peptide derived from bee venom, has attracted sustained interest in nanomedicine because of its broad anticancer, antiviral, and anti-inflammatory activities. These effects arise not only from direct membrane disruption, but also from secondary intracellular stress signaling and context-dependent immunomodulatory responses. The same mechanism, however, also underlies melittin’s major limitation: potent biological activity is closely coupled to hemolysis, nonspecific cytotoxicity, and poor systemic tolerability. For this reason, the central question in melittin nanomedicine is no longer whether the peptide is bioactive, but how that activity can be spatially, temporally, and pharmacologically constrained in vivo. Nanocarrier engineering has therefore become integral to melittin development, with lipidic, polymeric, inorganic, and hybrid systems being explored to reduce premature toxicity, improve lesion-site accumulation, regulate peptide release, and enable active or stimulus-responsive targeting. In this review, we synthesize current progress from three linked perspectives: the mechanistic basis of melittin action, the disease-specific logic of its reported applications, and the translational criteria that distinguish proof-of-concept platforms from development-relevant ones. This review was prepared by searching peer-reviewed literature published primarily between 2020 and early 2026 in PubMed, Web of Science, and Scopus, with priority given to studies addressing melittin biological activity, nanocarrier formulation design, toxicity modulation, and translational considerations. Across the current literature, the most decisive issues are not efficacy alone, but the extent to which toxicity attenuation, exposure control, PK/PD interpretability, and formulation tractability can be achieved within the same platform. The available evidence suggests that melittin is most plausibly advanced in delivery-controlled settings, particularly localized, route-constrained, or selected combination-oriented applications, whereas broader systemic use still requires stronger evidence in long-term safety, pharmacological standardization, and product-level reproducibility.
- 1 May 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-21
Open AccessNanocarrier-Enabled Melittin Therapy: Mechanistic Advances, Therapeutic Applications, and Translational Challenges
Melittin, a 26-amino-acid amphipathic peptide derived from bee venom, has attracted sustained interest in nanomedicine because of its broad anticancer, antiviral, and anti-inflammatory activities. These effects arise not only from direct membrane disruption, but also from secondary intracellular stress signaling and context-dependent immunomodulatory responses. The same mechanism, however, also underlies melittin’s major limitation: potent biological activity is closely coupled to hemolysis, nonspecific cytotoxicity, and poor systemic tolerability. For this reason, the central question in melittin nanomedicine is no longer whether the peptide is bioactive, but how that activity can be spatially, temporally, and pharmacologically constrained in vivo. Nanocarrier engineering has therefore become integral to melittin development, with lipidic, polymeric, inorganic, and hybrid systems being explored to reduce premature toxicity, improve lesion-site accumulation, regulate peptide release, and enable active or stimulus-responsive targeting. In this review, we synthesize current progress from three linked perspectives: the mechanistic basis of melittin action, the disease-specific logic of its reported applications, and the translational criteria that distinguish proof-of-concept platforms from development-relevant ones. This review was prepared by searching peer-reviewed literature published primarily between 2020 and early 2026 in PubMed, Web of Science, and Scopus, with priority given to studies addressing melittin biological activity, nanocarrier formulation design, toxicity modulation, and translational considerations. Across the current literature, the most decisive issues are not efficacy alone, but the extent to which toxicity attenuation, exposure control, PK/PD interpretability, and formulation tractability can be achieved within the same platform. The available evidence suggests that melittin is most plausibly advanced in delivery-controlled settings, particularly localized, route-constrained, or selected combination-oriented applications, whereas broader systemic use still requires stronger evidence in long-term safety, pharmacological standardization, and product-level reproducibility.
- Open Access
- 17 April 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Diagnosis and treatment of abdominal pain of spinal origin: a case report
Clinically, abdominal pain can also be caused by lesions of the vertebral bodies, intervertebral discs, and other structures. It is usually due to degenera
- 17 April 2026
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 20 (1)
Open AccessDiagnosis and treatment of abdominal pain of spinal origin: a case report
Clinically, abdominal pain can also be caused by lesions of the vertebral bodies, intervertebral discs, and other structures. It is usually due to degenera
- Open Access
- 1 April 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-10
Advances in Nano-Drug Delivery Systems for Osteosarcoma: From Targeting Strategies to Combating Lung Metastasis
Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children and adolescents, characterized by aggressive local invasion, early distant metastasis (predominantly lung metastasis), and poor prognosis. Conventional clinical regimens, mainly neoadjuvant chemotherapy combined with surgical resection, are limited by severe systemic toxicity, multidrug resistance, low tumor targeting, and unsatisfactory outcomes for metastatic OS, with the 5-year survival rate of metastatic patients remaining below 30%. Nanodrug delivery systems (NDDS) have emerged as a transformative strategy to address these bottlenecks by enabling targeted drug/gene delivery, controlled release, enhanced tumor accumulation, and reduced off-target effects. This review systematically summarizes the pathological characteristics and therapeutic dilemmas of OS, highlights recent advances in diverse NDDS including lipid nanoparticles, polymeric nanoparticles, carbon-based nanomaterials, extracellular vesicles, gold nanoparticles, and hydrogels for OS therapy, with a special focus on strategies to counteract lung metastasis. We further discuss the clinical translation challenges of NDDS in OS, especially pediatric-specific concerns, and propose future directions such as stimuli-responsive nanocarriers, biomimetic nanoparticles, combination therapy, and inhalable nanomedicines for pulmonary metastatic lesions. Overall, NDDS hold great promise to revolutionize OS treatment by improving therapeutic efficacy and safety, particularly in overcoming lung metastasis and chemoresistance.
- 1 April 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-10
Open AccessAdvances in Nano-Drug Delivery Systems for Osteosarcoma: From Targeting Strategies to Combating Lung Metastasis
Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children and adolescents, characterized by aggressive local invasion, early distant metastasis (predominantly lung metastasis), and poor prognosis. Conventional clinical regimens, mainly neoadjuvant chemotherapy combined with surgical resection, are limited by severe systemic toxicity, multidrug resistance, low tumor targeting, and unsatisfactory outcomes for metastatic OS, with the 5-year survival rate of metastatic patients remaining below 30%. Nanodrug delivery systems (NDDS) have emerged as a transformative strategy to address these bottlenecks by enabling targeted drug/gene delivery, controlled release, enhanced tumor accumulation, and reduced off-target effects. This review systematically summarizes the pathological characteristics and therapeutic dilemmas of OS, highlights recent advances in diverse NDDS including lipid nanoparticles, polymeric nanoparticles, carbon-based nanomaterials, extracellular vesicles, gold nanoparticles, and hydrogels for OS therapy, with a special focus on strategies to counteract lung metastasis. We further discuss the clinical translation challenges of NDDS in OS, especially pediatric-specific concerns, and propose future directions such as stimuli-responsive nanocarriers, biomimetic nanoparticles, combination therapy, and inhalable nanomedicines for pulmonary metastatic lesions. Overall, NDDS hold great promise to revolutionize OS treatment by improving therapeutic efficacy and safety, particularly in overcoming lung metastasis and chemoresistance.
- Top Cited PapersOpen Access
- 1 April 2026
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 21, 1-14
Targeted Decompression Under Local Anesthesia versus Extensive Decompression Under General Anesthesia for Octogenarians with Lumbar Degenerative Diseases: A Real-World Propensity Score-Matched Analysis
Background: Surgical management of lumbar degenerative diseases (LDD) in octogenarians requires balancing effective neural decompression against diminishing physiological reserves. While general anesthesia (GA)-based endoscopic techniques (ENDO-GA) are highly effective, they often impose excessive systemic stress on frail patients. Conversely, percutaneous endoscopic lumbar discectomy under local anesthesia (PELD-LA) provides targeted decompression while mitigating these GA-associated risks. Given the scarcity of direct comparisons in this fragile population, this study evaluates the safety and efficacy of PELD-LA versus ENDO-GA. Methods: We retrospectively analyzed 100 consecutive octogenarians treated for LDD between January 2021 and December 2024. Patients were stratified into two specific surgical strategy groups: targeted decompression via PELD-LA (n=54) and extensive decompression via ENDO-GA (utilizing UBE or Delta techniques, n=46). To minimize selection bias, a 1:1 Propensity Score Matching (PSM) was conducted using specific covariates (age, sex, comorbidities, and ASA classification), yielding 39 matched pairs (n=78). Primary outcomes assessed perioperative safety and recovery efficiency (complications, PONV, ambulation time, and length of hospital stay).Secondary outcomes evaluated postoperative clinical efficacy (VAS and ODI at 3 months, and modified MacNab criteria at 12 months postoperatively). Results: After propensity score matching, baseline characteristics were well-balanced between the two groups. Perioperatively, the PELD-LA group exhibited significantly shorter operative times (97 vs 150 min, P< 0.001), earlier ambulation (48 vs 72 h, P< 0.001), and reduced length of hospital stay (9 vs 14 days, P< 0.001) compared to the ENDO-GA group. Clinically, despite a smaller “targeted” decompression range, PELD-LA achieved long-term efficacy (MacNab criteria: 94.9% vs 94.9%, P=1.000) comparable to extensive decompression, while demonstrating superior early pain relief and functional improvement (VAS and ODI) at 3 months postoperatively (P< 0.01). Crucially, the overall complication rate was significantly lower in the PELD-LA group (30.8% vs 82.1%, P< 0.001), primarily driven by a marked reduction in postoperative nausea and vomiting (PONV) (23.1% vs 66.7%, P< 0.001). Conclusion: Within our short-to-medium-term observation period, PELD-LA delivered clinical efficacy comparable to GA-based endoscopic procedures for octogenarians, while significantly reducing perioperative complications and accelerating recovery. Crucially, we do not assert that PELD-LA is universally superior; rather, we emphasize the importance of tailored patient selection. For frail patients with limited physiological reserve, PELD-LA serves as a physiologically rational strategy, balancing targeted decompression with the preservation of systemic stability.
- 1 April 2026
- Published by Taylor & Francis in Clinical Interventions in Aging
- Vol. ume 21, 1-14
Top Cited PapersOpen AccessTargeted Decompression Under Local Anesthesia versus Extensive Decompression Under General Anesthesia for Octogenarians with Lumbar Degenerative Diseases: A Real-World Propensity Score-Matched Analysis
Background: Surgical management of lumbar degenerative diseases (LDD) in octogenarians requires balancing effective neural decompression against diminishing physiological reserves. While general anesthesia (GA)-based endoscopic techniques (ENDO-GA) are highly effective, they often impose excessive systemic stress on frail patients. Conversely, percutaneous endoscopic lumbar discectomy under local anesthesia (PELD-LA) provides targeted decompression while mitigating these GA-associated risks. Given the scarcity of direct comparisons in this fragile population, this study evaluates the safety and efficacy of PELD-LA versus ENDO-GA. Methods: We retrospectively analyzed 100 consecutive octogenarians treated for LDD between January 2021 and December 2024. Patients were stratified into two specific surgical strategy groups: targeted decompression via PELD-LA (n=54) and extensive decompression via ENDO-GA (utilizing UBE or Delta techniques, n=46). To minimize selection bias, a 1:1 Propensity Score Matching (PSM) was conducted using specific covariates (age, sex, comorbidities, and ASA classification), yielding 39 matched pairs (n=78). Primary outcomes assessed perioperative safety and recovery efficiency (complications, PONV, ambulation time, and length of hospital stay).Secondary outcomes evaluated postoperative clinical efficacy (VAS and ODI at 3 months, and modified MacNab criteria at 12 months postoperatively). Results: After propensity score matching, baseline characteristics were well-balanced between the two groups. Perioperatively, the PELD-LA group exhibited significantly shorter operative times (97 vs 150 min, P< 0.001), earlier ambulation (48 vs 72 h, P< 0.001), and reduced length of hospital stay (9 vs 14 days, P< 0.001) compared to the ENDO-GA group. Clinically, despite a smaller “targeted” decompression range, PELD-LA achieved long-term efficacy (MacNab criteria: 94.9% vs 94.9%, P=1.000) comparable to extensive decompression, while demonstrating superior early pain relief and functional improvement (VAS and ODI) at 3 months postoperatively (P< 0.01). Crucially, the overall complication rate was significantly lower in the PELD-LA group (30.8% vs 82.1%, P< 0.001), primarily driven by a marked reduction in postoperative nausea and vomiting (PONV) (23.1% vs 66.7%, P< 0.001). Conclusion: Within our short-to-medium-term observation period, PELD-LA delivered clinical efficacy comparable to GA-based endoscopic procedures for octogenarians, while significantly reducing perioperative complications and accelerating recovery. Crucially, we do not assert that PELD-LA is universally superior; rather, we emphasize the importance of tailored patient selection. For frail patients with limited physiological reserve, PELD-LA serves as a physiologically rational strategy, balancing targeted decompression with the preservation of systemic stability.
- Open Access
- 26 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1660852
Tumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment
Background: Abnormal protein glycosylation is a key feature of tumors. Among the modifications, Tn antigen (GalNAcα1-Ser/Thr) and its sialylated derivative, STn antigen (Neu5Acα2-6GalNAcα1-O-Ser/Thr), are prominent tumor-associated carbohydrate antigens. These antigens exhibit abnormal accumulation in epithelial malignancies, including colorectal cancer, breast cancer, and pancreatic cancer. Their pathological overexpression primarily stems from inactivation of the COSMC/T-synthase axis, either due to genetic mutations or epigenetic silencing, leading to truncated O-glycan biosynthesis. Findings: Tn/STn antigens directly promote tumor progression by activating oncogenic signaling pathways (e.g., EGFR/FAK) and inducing epithelial-mesenchymal transition. Additionally, these antigens play a noticeable role in immune suppression in the tumor microenvironment. Tn antigens bind to macrophage galactose-specific lectin (MGL) on myeloid cells, while STn antigens interact with sialic acid-binding immunoglobulin-like lectins (Siglecs), collectively inhibiting natural killer cell cytotoxicity, dendritic cell maturation, and T cell activation. Changes in serum levels of glycoprotein tumor markers (e.g., CA15–3 and CA125) are associated with aberrant protein glycosylation in cancer cells, which may influence their expression levels, stability, or immunodetection. Current therapeutic approaches include monoclonal antibodies (e.g., Remab6, L2A5), antibody-drug conjugates, CAR-T cell therapies, and vaccines. However, challenges remain due to glycan heterogeneity and low immunogenicity. Conclusion: Tn/STn antigens play a pivotal role in tumorigenesis and immune evasion, presenting significant potential for both diagnostic and therapeutic applications. Future research should concentrate on elucidating the underlying mechanisms, developing innovative detection technologies, and promoting multidisciplinary collaborations to advance Tn/STn antigen-based tumor molecular subtyping, precision targeted therapies, and efficacy prediction systems, thereby providing new directions for cancer diagnosis and treatment.
- 26 November 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1660852
Open AccessTumor-associated Tn and STn antigens: from molecular mechanism to precision diagnosis and treatment
Background: Abnormal protein glycosylation is a key feature of tumors. Among the modifications, Tn antigen (GalNAcα1-Ser/Thr) and its sialylated derivative, STn antigen (Neu5Acα2-6GalNAcα1-O-Ser/Thr), are prominent tumor-associated carbohydrate antigens. These antigens exhibit abnormal accumulation in epithelial malignancies, including colorectal cancer, breast cancer, and pancreatic cancer. Their pathological overexpression primarily stems from inactivation of the COSMC/T-synthase axis, either due to genetic mutations or epigenetic silencing, leading to truncated O-glycan biosynthesis. Findings: Tn/STn antigens directly promote tumor progression by activating oncogenic signaling pathways (e.g., EGFR/FAK) and inducing epithelial-mesenchymal transition. Additionally, these antigens play a noticeable role in immune suppression in the tumor microenvironment. Tn antigens bind to macrophage galactose-specific lectin (MGL) on myeloid cells, while STn antigens interact with sialic acid-binding immunoglobulin-like lectins (Siglecs), collectively inhibiting natural killer cell cytotoxicity, dendritic cell maturation, and T cell activation. Changes in serum levels of glycoprotein tumor markers (e.g., CA15–3 and CA125) are associated with aberrant protein glycosylation in cancer cells, which may influence their expression levels, stability, or immunodetection. Current therapeutic approaches include monoclonal antibodies (e.g., Remab6, L2A5), antibody-drug conjugates, CAR-T cell therapies, and vaccines. However, challenges remain due to glycan heterogeneity and low immunogenicity. Conclusion: Tn/STn antigens play a pivotal role in tumorigenesis and immune evasion, presenting significant potential for both diagnostic and therapeutic applications. Future research should concentrate on elucidating the underlying mechanisms, developing innovative detection technologies, and promoting multidisciplinary collaborations to advance Tn/STn antigen-based tumor molecular subtyping, precision targeted therapies, and efficacy prediction systems, thereby providing new directions for cancer diagnosis and treatment.
- Open Access
- 1 November 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 6371-6379
Early Outcomes of Unilateral Biportal Endoscopic Decompression for Adjacent Segment Disease After Lumbar Fusion
Purpose: To study the early curative effect of unilateral biportal endoscopy (UBE) in the treatment of adjacent segment disease after lumbar interbody fusion. Methods: A retrospective analysis of clinical data from 58 patients diagnosed with adjacent segment disease subsequent to lumbar fusion surgery who were treated using the UBE technique between June 2019 and June 2024 at our institution was conducted. The patients’ operation time, intraoperative bleeding, postoperative hospitalization time, and the occurrence of complications were recorded. The visual analogue scale (VAS) for pain, the Japanese Orthopaedic Association (JOA) score, and the Oswestry Dysfunction Index (ODI) for lumbar function were utilised before and after surgery, and the MacNab criteria were employed to evaluate the patient’s outcome at six months after surgery. Results: The operation time was between 55 and 189 minutes, mean 102.64 minutes, the postoperative drainage flow was between 10 and 110 mL mean 47.81 mL, and the length of hospital stay between 5 and 14 days, mean 9.41 days. VAS scores of pain decreased over time and the ODI index was consistently lower than preoperative at all stages of the postoperative period. JOA scores increased gradually at all postoperative times. All indexes differed statistically at all times (P< 0.05). Surgical efficacy was excellent in 93.1% of cases at 6 months. Conclusion: The UBE technique is an alternative surgical procedure for the treatment of adjacent segment disease after lumbar fusion, under strict control of the indications.
- 1 November 2025
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 18, 6371-6379
Open AccessEarly Outcomes of Unilateral Biportal Endoscopic Decompression for Adjacent Segment Disease After Lumbar Fusion
Purpose: To study the early curative effect of unilateral biportal endoscopy (UBE) in the treatment of adjacent segment disease after lumbar interbody fusion. Methods: A retrospective analysis of clinical data from 58 patients diagnosed with adjacent segment disease subsequent to lumbar fusion surgery who were treated using the UBE technique between June 2019 and June 2024 at our institution was conducted. The patients’ operation time, intraoperative bleeding, postoperative hospitalization time, and the occurrence of complications were recorded. The visual analogue scale (VAS) for pain, the Japanese Orthopaedic Association (JOA) score, and the Oswestry Dysfunction Index (ODI) for lumbar function were utilised before and after surgery, and the MacNab criteria were employed to evaluate the patient’s outcome at six months after surgery. Results: The operation time was between 55 and 189 minutes, mean 102.64 minutes, the postoperative drainage flow was between 10 and 110 mL mean 47.81 mL, and the length of hospital stay between 5 and 14 days, mean 9.41 days. VAS scores of pain decreased over time and the ODI index was consistently lower than preoperative at all stages of the postoperative period. JOA scores increased gradually at all postoperative times. All indexes differed statistically at all times (P< 0.05). Surgical efficacy was excellent in 93.1% of cases at 6 months. Conclusion: The UBE technique is an alternative surgical procedure for the treatment of adjacent segment disease after lumbar fusion, under strict control of the indications.
- Open Access
- 1 October 2025
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 50 (4) , 365-381
Lung macrophages in pulmonary homeostasis and disease: from basic biology to clinical applications
Lung macrophages, as key components of the pulmonary immune system, exert multiple key functions in maintaining pulmonary homeostasis and immune defense by eliminating pathogens (such as bacteria and viruses), modulating inflammatory responses, participating in antigen presentation, and promoting tissue repair. This review summarizes the fundamental biological functions of lung macro- phages and explores their mechanisms of action in diseases such as acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), influenza, tuberculosis (TB) and lung cancer. Mounting evidence highlights the crucial link between macrophage dysfunction and disease progression. With the advent of advanced technologies such as single-cell transcriptomics, CRISPR gene editing, and proteomics, our understanding of lung macrophage heterogeneity, developmental origins, and functional landscapes has significantly expanded. However, challenges remain in the field, and future research requires interdisciplinary efforts to unravel the molecular mechanisms of macrophages in disease and to develop novel therapeutic targets and strategies for the prevention and treatment of lung diseases.
- 1 October 2025
- Published by Termedia Sp. z.o.o. in Central European Journal of Immunology
- Vol. 50 (4) , 365-381
Open AccessLung macrophages in pulmonary homeostasis and disease: from basic biology to clinical applications
Lung macrophages, as key components of the pulmonary immune system, exert multiple key functions in maintaining pulmonary homeostasis and immune defense by eliminating pathogens (such as bacteria and viruses), modulating inflammatory responses, participating in antigen presentation, and promoting tissue repair. This review summarizes the fundamental biological functions of lung macro- phages and explores their mechanisms of action in diseases such as acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), influenza, tuberculosis (TB) and lung cancer. Mounting evidence highlights the crucial link between macrophage dysfunction and disease progression. With the advent of advanced technologies such as single-cell transcriptomics, CRISPR gene editing, and proteomics, our understanding of lung macrophage heterogeneity, developmental origins, and functional landscapes has significantly expanded. However, challenges remain in the field, and future research requires interdisciplinary efforts to unravel the molecular mechanisms of macrophages in disease and to develop novel therapeutic targets and strategies for the prevention and treatment of lung diseases.
- 13 January 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 249, 114512
Aptamer-modified melittin micelles efficiently inhibit osteosarcoma deterioration by inducing immunogenic cell death
- 13 January 2025
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 249, 114512
Aptamer-modified melittin micelles efficiently inhibit osteosarcoma deterioration by inducing immunogenic cell death